ga('create', 'UA-58416928-1', 'auto'); ga('send', 'pageview'); skip to primary navigationskip to content

Special Seminar - Claudio Koser : Redefining susceptibility and resistance to anti-tuberculosis drugs

When Mar 19, 2018
from 12:30 PM to 01:30 PM
Add event to calendar vCal

On Monday, 19th March, at 12:30 ex-Part II and Postgraduate in the Department, Dr Claudio Köser will be presenting a Seminar titled Redefining susceptibility and resistance to anti-tuberculosis drugs.  Come to the Part II room on Monday to learn more.


Traditionally, the World Health Organization (WHO) had relied on expert opinion to set breakpoints for phenotypic drug-susceptibility testing (pDST) for the Mycobacterium tuberculosis complex, the causative agent of tuberculosis (TB). However, the evidence had been mounting that some of these breakpoints were flawed. To remedy these issues, I convinced WHO to adopt modern microbiological principles and became the lead analyst of a systematic review to revise or set the breakpoints for eight second-line and two new anti-TB drugs. Based on our recommendations, WHO established or revised 20 breakpoints. Importantly, five breakpoints for fluoroquinolones or second-line injectables, which represent the backbone of the regimens for drug-resistant TB, were lowered. In other words, some strains that were resistant to these drugs were systematically misclassified as susceptible using the old breakpoints, which likely resulted in inappropriate treatment of thousands of patients and avoidable deaths. The new breakpoints will now be adopted globally by diagnostic laboratories for pDST.